The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients.

Fiche publication

Date publication

mars 2022

Journal

Journal of neuro-oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr FOUYSSAC Fanny

Tous les auteurs :
de Marcellus C, Tauziède-Espariat A, Cuinet A, Pasqualini C, Robert MP, Beccaria K, Puget S, Boddaert N, Figarella-Branger D, De Carli E, Bourdeaut F, Leblond P, Fouyssac F, Andre N, Bertozzi AI, Butel T, Dufour C, Valteau-Couanet D, Varlet P, Grill J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35239111

Résumé

At least half of children with low-grade glioma (LGG) treated with first line chemotherapy experience a relapse/progression and may therefore need a second-line chemotherapy. Irinotecan-bevacizumab has been recommended in this setting in France after encouraging results of pilot studies. We performed a retrospective analysis to define the efficacy, toxicity and predictors for response to the combination on a larger cohort.